All News
ACR21 Best Abstracts - Day 1
The RheumNow faculty have been glued to their monitors all day, watching video, and running down abstract presentations to find the best – several of these stood out as #ACRBests. Here is a listing of “Best” they saw on Day 1.
Read Article
Work participation in patients with axial spondyloarthritis
Patients with axial spondyloarthritis (axSpA) often have increased absence from work as well as reduced productivity at work, which can have profound impacts for not only the affected individual and their families, but also lead to wider economic and social burden.
Read Article
Abst0919 #ACR21 @RheumNow Phase III COAST-V 52W (PBO)-controlled study examined the efficacy of IXE in pts with active AS. SF-36 bodily pain, improvements were observed at W16 & W52 whether inflammation was controlled or not per MRI, CRP, MRI+CRP, or BASDAI 5/6. https://t.co/uHLwFctzPr
Olga Petryna DrPetryna ( View Tweet)
2 year extension study on Upadacitinib in active AS
⭐️ASAS40 response maintained
⭐️MRI SPARCC scores decreased and maintained
⭐️infections most common AE
⭐️NO MACE, lymphoma, skin cancer, GI perforations
Abs#924
#ACR21 #ACRBest
@RheumNow
https://t.co/725IRAOgtW https://t.co/FVUoCi6aoQ
Robert B Chao, MD doctorRBC ( View Tweet)
No significant difference in effectiveness/treatment survival of different TNFi in axSpA
Failure of 1st TNFi did not diminish effectiveness of a second TNFi
Abs#938
#ACR21 @RheumNow
https://t.co/SLrOV7wmvU https://t.co/fkpmseVwF6
Robert B Chao, MD doctorRBC ( View Tweet)
Abst 0947 #ACR21 @RheumNow KikGR x TNFDARE/+ mice study assessed contribution of gut-derived T cells to increased joint inflammation through production of pro-inflammatory cytokines like IL-17 and TNF. Photolabeled gut-trafficked T cells are observed in the Achilles enthesis
Olga Petryna DrPetryna ( View Tweet)
No evidence to show increased risk of incident hypertension w/ TNFi use, after accounting for baseline & time-dependent confounding factors, in prospective AS cohort. Abs 0910 #ACR21 #RheumNow @RheumNow https://t.co/1SpQ51ftlK
Dr. Rachel Tate uptoTate ( View Tweet)
French, real-world axSpA cohort analysis shows SEC and TNFi retention rates similar. What do you see in your practice? Abs 0911 #ACR21 #RheumNow @RheumNow https://t.co/vu3zUwfktl https://t.co/v6DLjWJMn4
Dr. Rachel Tate uptoTate ( View Tweet)
@rheum_cat presenting a really well designed study looking at association between TNFi use and incident hypertension in axSpA. No association found. Abstr#0910 #ACR21 @RheumNow https://t.co/w7o1oDreVL
Richard Conway RichardPAConway ( View Tweet)
Abst0569 #acr21 @RheumNow mortality in SpA:⬆️ overall mortality in AS (RR 1.64, 95% CI: 1.49-1.80,) but not PsA (RR: 1.12, 95% CI: 0.96-1.30). CV, resp & infection specific mortality significantly higher for PsA Cancer related mortality in PsA not higher than the gen pop
Olga Petryna DrPetryna ( View Tweet)
Abst 0562
Ungprasert & colleagues examine hospitalization and resource utilization among patients with #AnkylosingSpondylitis
- Prevalence is high
- Infection was among the most common reasons for hospitalization (sepsis, pneumonia, UTI)
#ACR21 @RheumNow https://t.co/UftoFllE1v
Akhil Sood MD AkhilSoodMD ( View Tweet)
Abst0907 #ACR21 @RheumNow observation of GLAS cohort of nrAxSpA pts over 6 yrs showed ~10% of pts progress to AS every 2 years. Specifically after two, four and six years, 8/79 (10.1%), 4/48 (8.3%) and 3/24 (12.5%) nr-axSpA patients progressed to AS. https://t.co/hVpNz1kEgE
Olga Petryna DrPetryna ( View Tweet)
Prospective multicenter Screening for Axial Spondyloarthritis in Psoriasis, Iritis, and Colitis Study evaluated 240 patients with axSpA
⭐️Imaging of the SIJ and spine DOES NOT differ in Ps axSpA or axSpA associated with iritis or colitis
Abst# 0902 #ACR21 #ACRBest @RheumNow https://t.co/Y2bRlysXI5
swethaann23 swethaann23 ( View Tweet)
The rate of progression of nr-axSpA to AS is ~10% every 2 years. Study of 79 patients over 6 years, radiographic progression was 10.1% after 2 years (8/79), 8.3% between 2-4 years (4/48), and 12.5% between 4-6 years (3/24) @RheumNow #ACR21 Abst#0907 https://t.co/hOhpngANIl https://t.co/PiKDgiTES2
Dr. Antoni Chan synovialjoints ( View Tweet)
Interim analysis of real world data on AQUILA (Dr Uta Kiltz et al): how gender affects SEC tx and retention rates:
🔷Improvement in BASDAI, PGA, global fnxn & depressive mood - similar in both ♂️&♀️
🔷High SEC retention rates irrespective of gender
@RheumNow #ACR21 abs909 https://t.co/rXa6ELXDJo
sheila RHEUMarampa ( View Tweet)
Interesting study by @DrPoddubnyy et al. looking into the efficacy of SEC on HLAB27 subtypes (post hoc analysis of SKIPPAIN trial)
➡ SEC effective for both HLAB27+ and - grps
➡ Significant response seen among HLAB27+ and HLAB27 homozygous pts
@RheumNow #ACR21 abs0917 https://t.co/St37kdGY65
sheila RHEUMarampa ( View Tweet)
Radiographic progression in AS is greatest between ages 30-39. The presence of preexisting structural damage starts to accelerate it from earlier ages. Data from 1125 patients followed from 2001-2018 @RheumNow #ACR21 Abst#0897 https://t.co/g0t45R0lOd https://t.co/RvlO9EcMIX
Dr. Antoni Chan synovialjoints ( View Tweet)
Gender differences in secukinumab treatment of AS?
⭐️improved disease activity, global function, depression in men and women
⭐️women ⬆️disease burden
⭐️high retention rates irrespective of gender
Abs#909
#ACR21 @RheumNow
https://t.co/L6mCxuSMo1 https://t.co/pR3OBoXqaT
Robert B Chao, MD doctorRBC ( View Tweet)
Drug retention of TNFi vs. secukinumab in AxSpA pts
Abs#911
⭐️46% discontinued either treatment
⭐️TNFi with slightly better drug retention
⭐️Age, BASDAI, BMI did not favor any group
⭐️inefficacy - main reason
#ACR21 @RheumNow https://t.co/ynoomYrTvX
Robert B Chao, MD doctorRBC ( View Tweet)
Detecting inflammation in SIJ for axSpA is by MRI but Artificial intelligence convolutional network aids this:
-In the Validation set: Trained CNN ▶️91.8% accuracy; Sens 88.9% Sp 93.5%
- Holdout set: 81.5% accuracy; Sens 67%; Sp 84.5%.
Abst# 0905 #ACR21 #ACRBest @RheumNow https://t.co/qmOxk9JQOC
swethaann23 swethaann23 ( View Tweet)
